Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

I am not a Healthcare Professional

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Prescribing and adverse event reporting information found at the bottom of the page.

global-header-image
  • Products
    • Forxiga® (dapagliflozin)
    • Lokelma® (sodium zirconium cyclosilicate)
    • IMFINZI® (durvalumab)
    • IMJUDO®▼ (tremelimumab)
    • Symbicort® (budesonide/formoterol)
    • Tezspire®▼ (tezepelumab)
    • Trixeo Aerosphere® (formoterol fumarate dihydrate/glycopyrronium/budesonide)
  • Therapeutic Areas
    • Cardiovascular
    • Metabolic
    • Renal
    • Respiratory
  • About us
    • AZ Commitment
  • Contact us
  • AstraZeneca UK

Welcome to MyAstraZeneca.

Welcome to MyAstraZeneca.

Welcome to MyAstraZeneca.

Welcome to MyAstraZeneca.

  1. first-slide
  2. sec-slide
  3. third-slide
  4. fourth-slide

How can we help you today?

Discover our commitment to respiratory care
Learn more about Cardiovascular
Understand our work in Renal
See our latest impact in Metabolic


Prescribing Information 

FORXIGA® (dapagliflozin) Prescribing Information
LOKELMA® (sodium zirconium cyclosilicate) Prescribing Information

IMFINZI® (durvalumab) Prescribing Information

IMJUDO® (tremelimumab) ▼ Prescribing Information

SYMBICORT®(budesonide/formoterol) Asthma Prescribing Information
SYMBICORT®(budesonide/formoterol) COPD 200/6 and 400/12 Prescribing Information
SYMBICORT®(budesonide/formoterol) COPD Prescribing Information
TEZSPIRE®▼(tezepelumab) Prescribing Information
TRIXEO®(formoterol fumarate dihydrate/ glycopyrronium/budesonide) Prescribing Information

Contact us

If you have any questions about AstraZeneca medicines or would like to speak to our representative, please contact us.

Click here to get in touch with us

GB-66264 | DOP: April 2025

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Connessiallasalute.it

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Terms of use

Privacy Policy

Cookie Policy

Contact Us

LinkedIn

Twitter

©2025 AstraZeneca. GB-66285 | DOP: April 2025